Penumbra Free Cash Flow 2014-2024 | PEN

Penumbra free cash flow for the twelve months ending September 30, 2024 was , a year-over-year.

  • Penumbra annual free cash flow for 2023 was $0.081B, a 208.24% decline from 2022.
  • Penumbra annual free cash flow for 2022 was $-0.075B, a 541.88% increase from 2021.
  • Penumbra annual free cash flow for 2021 was $-0.012B, a 64.87% decline from 2020.

Penumbra Free Cash Flow 2014-2024 | PEN

  • Penumbra annual free cash flow for 2023 was $0.081B, a 208.24% decline from 2022.
  • Penumbra annual free cash flow for 2022 was $-0.075B, a 541.88% increase from 2021.
  • Penumbra annual free cash flow for 2021 was $-0.012B, a 64.87% decline from 2020.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$197.6B
Intuitive Surgical (ISRG)$186.6B
Edwards Lifesciences (EW)$43.6B
Alcon (ALC)$41.5B
IQVIA Holdings (IQV)$34.8B
IDEXX Laboratories (IDXX)$33.5B
DexCom (DXCM)$29.6B
Waters (WAT)$21.4B
STERIS (STE)$20.2B
SONOVA HOLDING (SONVY)$19.4B
Hologic (HOLX)$16.1B
Fresenius Medical Care AG KGaA (FMS)$13.2B
Sysmex ADR (SSMXY)$11.7B
Globus Medical (GMED)$11.2B
Masimo (MASI)$9.1B
Teleflex (TFX)$8.1B
Glaukos (GKOS)$7.9B
Integer Holdings (ITGR)$4.5B
PROCEPT BioRobotics (PRCT)$4.2B
Inari Medical (NARI)$3.2B
Veracyte (VCYT)$3B
Nihon Kohden (NHNKY)$2.6B
LivaNova (LIVN)$2.6B
Tandem Diabetes Care (TNDM)$2.2B
Elekta AB (EKTAY)$2.1B
TransMedics (TMDX)$2B
Integra LifeSciences Holdings (IART)$1.7B
RxSight (RXST)$1.5B
Alphatec Holdings (ATEC)$1.3B
Artivion (AORT)$1.2B